English

Syndax Pharmaceuticals Inc

EDGAR

SNDX Quarterly report (10-Q) · filed 2026-08-04

Annual consolidated revenue for 2025: about USD 172.4M, using the latest reported figures. The previous period, 2024, was about USD 23.68M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

72.8 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 72788000 USD Source

Operating margin

-54.95%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -39995000 USD Source
Revenue: 72788000 USD Source

Operating cash flow

-30.3 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -80617000 USD Source
Operating Cash Flow: -50345000 USD Source

Cash and cash equivalents: 336 million USD 2026-06-30 Source
Exact value

336477000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 89.2 million shares 2026-06-30 Source
Exact value

89150619 shares

Reported share-count change

3.59% · 3.09 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

86059077 shares · 2025-06-30· Source
89150619 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

252 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 45871000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 172352000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 103624000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 64864000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 72788000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-221 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -60715000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -285422000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -217408000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -42673000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -49363000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-221 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -253492000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -182957000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -322980000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -253492000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -50345000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -80617000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -50345000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

187 thousand USD

2018-01-01 – 2018-12-31

Exact inputs and evidence

Capital expenditure: 173000 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 173000 USD · 2018-01-01 – 2018-06-30 Source
Capital expenditure: 173000 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 173000 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 173000 USD · 2018-01-01 – 2018-06-30 Source
Capital expenditure: 187000 USD · 2018-01-01 – 2018-12-31 Source
Capital expenditure: 173000 USD · 2018-01-01 – 2018-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-04.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 10 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+627.8%

Prior period

USD 23.68 million

2024-01-01 – 2024-12-31
Current period

USD 172.35 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

172352000 − 23680000 = 148672000 USD

23680000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
172352000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Syndax Pharmaceuticals Inc · 2025-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Year-over-year change in Revenue: 148672000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 172352000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#1692692 Filing: 000119312526076536 Input fundies:Revenue: 23680000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#1694441 Filing: 000119312526076536
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 33.34 million

Prior period

−USD 318.76 million

2024-01-01 – 2024-12-31
Current period

−USD 285.42 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-285422000 − -318758000 = 33336000 USD

-318758000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-285422000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Syndax Pharmaceuticals Inc · 2025-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Year-over-year change in Net income: 33336000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -285422000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2545856 Filing: 000119312526076536 Input fundies:NetIncome: -318758000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2547708 Filing: 000119312526076536
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 48.08 million

Prior period

−USD 274.9 million

2024-01-01 – 2024-12-31
Current period

−USD 322.98 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-322980000 − -274903000 = -48077000 USD

-274903000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-322980000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Syndax Pharmaceuticals Inc · 2025-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Year-over-year change in Operating cash flow: -48077000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -322980000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2234462 Filing: 000119312526076536 Input fundies:OperatingCashFlow: -274903000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2236356 Filing: 000119312526076536
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+USD 187,000

Prior period

USD 0

2024-01-01 – 2024-12-31
Current period

USD 187,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

187000 − 0 = 187000 USD

0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
187000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Syndax Pharmaceuticals Inc · 2025-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Year-over-year change in Capital expenditure: 187000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 187000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2244148 Filing: 000119312526076536 Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2245811 Filing: 000119312526076536
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 172.35 million 100% of revenue
Operating costs Derived USD 445.44 million 258% of revenue
Operating income −USD 273.08 million −158% of revenue
Tax, interest and other Derived USD 12.34 million 7.2% of revenue
Net income −USD 285.42 million −166% of revenue

Cash

Operating cash flow −USD 322.98 million −187% of revenue
Capital expenditure USD 187,000 0.1% of revenue
Free cash flow Derived −USD 323.17 million −188% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 3,687% of revenue.
2017 Operating loss: operating costs were 3,039% of revenue.
2018 Operating loss: operating costs were 5,102% of revenue.
2019 Operating loss: operating costs were 3,893% of revenue.
2020 Operating loss: operating costs were 4,808% of revenue.
2021 18%81%
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Operating loss: operating costs were 1,534% of revenue.
2025 Operating loss: operating costs were 258% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	1220000	44986000 Derived	-43766000	706000 Derived	-44472000	-35418000 Derived	Source 2016-01-01 – 2016-12-31: 1220000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -43766000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -44472000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -35157000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 261000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	2108000	64062000 Derived	-61954000	-1152000 Derived	-60802000	-47455000 Derived	Source 2017-01-01 – 2017-12-31: 2108000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -61954000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -60802000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -47371000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 84000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	1517000	77393000 Derived	-75876000	-1915000 Derived	-73961000	-68718000 Derived	Source 2018-01-01 – 2018-12-31: 1517000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -75876000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -73961000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -68531000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 187000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	1517000	59056000 Derived	-57539000	-1492000 Derived	-56047000	Unavailable	Source 2019-01-01 – 2019-12-31: 1517000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -57539000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -56047000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -50612000 USD Inspect Operating Cash Flow Open source
2020 2020-01-01 – 2020-12-31	1517000	72940000 Derived	-71423000	1735000 Derived	-73158000	-71260000 Derived	Source 2020-01-01 – 2020-12-31: 1517000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -71423000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -73158000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -71260000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 0 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	139709000	113489000 Derived	26220000	1294000 Derived	24926000	29002000 Derived	Source 2021-01-01 – 2021-12-31: 139709000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 26220000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 24926000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 29131000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 129000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	0	151757000 Derived	-151757000	-2419000 Derived	-149338000	-133675000 Derived	Source 2022-01-01 – 2022-12-31: 0 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -151757000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -149338000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -133675000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 0 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	0	229954000 Derived	-229954000	-20594000 Derived	-209360000	-160601000 Derived	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -229954000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -209360000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -160601000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 0 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	23680000	363352000 Derived	-339672000	-20914000 Derived	-318758000	-274903000 Derived	Source 2024-01-01 – 2024-12-31: 23680000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -339672000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -318758000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -274903000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	172352000	445436000 Derived	-273084000	12338000 Derived	-285422000	-323167000 Derived	Source 2025-01-01 – 2025-12-31: 172352000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -273084000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -285422000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -322980000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 187000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 172.4M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	1220000	Revenue: 1220000 Open source
20172017-12-31	Revenue	2108000	Revenue: 2108000 Open source
20182018-12-31	Revenue	1517000	Revenue: 1517000 Open source
20192019-12-31	Revenue	1517000	Revenue: 1517000 Open source
20202020-12-31	Revenue	1517000	Revenue: 1517000 Open source
20212021-12-31	Revenue	139709000	Revenue: 139709000 Open source
20222022-12-31	Revenue	0	Revenue: 0 Open source
20232023-12-31	Revenue	0	Revenue: 0 Open source
20242024-12-31	Revenue	23680000	Revenue: 23680000 Open source
20252025-12-31	Revenue	172352000	Revenue: 172352000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

627.8% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	94.6%	Revenue: 1220000 Open source Revenue: 627000 Open source
20172017-12-31	Year over year	72.8%	Revenue: 2108000 Open source Revenue: 1220000 Open source
20182018-12-31	Year over year	-28%	Revenue: 1517000 Open source Revenue: 2108000 Open source
20192019-12-31	Year over year	0%	Revenue: 1517000 Open source Revenue: 1517000 Open source
20202020-12-31	Year over year	0%	Revenue: 1517000 Open source Revenue: 1517000 Open source
20212021-12-31	Year over year	9,109.6%	Revenue: 139709000 Open source Revenue: 1517000 Open source
20222022-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 139709000 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 23680000 Open source Revenue: 0 Open source
20252025-12-31	Year over year	627.8%	Revenue: 172352000 Open source Revenue: 23680000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -158.4% 2025

Net margin -165.6% 2025

Free cash flow margin -187.5% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-3,587.4%	Operating Income: -43766000 Open source Revenue: 1220000 Open source
20172017-12-31	Operating margin	-2,939%	Operating Income: -61954000 Open source Revenue: 2108000 Open source
20182018-12-31	Operating margin	-5,001.7%	Operating Income: -75876000 Open source Revenue: 1517000 Open source
20192019-12-31	Operating margin	-3,792.9%	Operating Income: -57539000 Open source Revenue: 1517000 Open source
20202020-12-31	Operating margin	-4,708.2%	Operating Income: -71423000 Open source Revenue: 1517000 Open source
20212021-12-31	Operating margin	18.8%	Operating Income: 26220000 Open source Revenue: 139709000 Open source
20222022-12-31	Operating margin	Not reported	Operating Income: -151757000 Open source Revenue: 0 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -229954000 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	-1,434.4%	Operating Income: -339672000 Open source Revenue: 23680000 Open source
20252025-12-31	Operating margin	-158.4%	Operating Income: -273084000 Open source Revenue: 172352000 Open source
20162016-12-31	Net margin	-3,645.2%	Net Income: -44472000 Open source Revenue: 1220000 Open source
20172017-12-31	Net margin	-2,884.3%	Net Income: -60802000 Open source Revenue: 2108000 Open source
20182018-12-31	Net margin	-4,875.5%	Net Income: -73961000 Open source Revenue: 1517000 Open source
20192019-12-31	Net margin	-3,694.6%	Net Income: -56047000 Open source Revenue: 1517000 Open source
20202020-12-31	Net margin	-4,822.5%	Net Income: -73158000 Open source Revenue: 1517000 Open source
20212021-12-31	Net margin	17.8%	Net Income: 24926000 Open source Revenue: 139709000 Open source
20222022-12-31	Net margin	Not reported	Net Income: -149338000 Open source Revenue: 0 Open source
20232023-12-31	Net margin	Not reported	Net Income: -209360000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	-1,346.1%	Net Income: -318758000 Open source Revenue: 23680000 Open source
20252025-12-31	Net margin	-165.6%	Net Income: -285422000 Open source Revenue: 172352000 Open source
20162016-12-31	Free cash flow margin	-2,903.1%	Revenue: 1220000 Open source Operating Cash Flow: -35157000 Open source Capital Expenditure: 261000 Open source
20172017-12-31	Free cash flow margin	-2,251.2%	Revenue: 2108000 Open source Operating Cash Flow: -47371000 Open source Capital Expenditure: 84000 Open source
20182018-12-31	Free cash flow margin	-4,529.9%	Revenue: 1517000 Open source Operating Cash Flow: -68531000 Open source Capital Expenditure: 187000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 1517000 Open source Operating Cash Flow: -50612000 Open source
20202020-12-31	Free cash flow margin	-4,697.4%	Revenue: 1517000 Open source Operating Cash Flow: -71260000 Open source Capital Expenditure: 0 Open source
20212021-12-31	Free cash flow margin	20.8%	Revenue: 139709000 Open source Operating Cash Flow: 29131000 Open source Capital Expenditure: 129000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -133675000 Open source Capital Expenditure: 0 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -160601000 Open source Capital Expenditure: 0 Open source
20242024-12-31	Free cash flow margin	-1,160.9%	Revenue: 23680000 Open source Operating Cash Flow: -274903000 Open source Capital Expenditure: 0 Open source
20252025-12-31	Free cash flow margin	-187.5%	Revenue: 172352000 Open source Operating Cash Flow: -322980000 Open source Capital Expenditure: 187000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -323M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-35157000	Operating Cash Flow: -35157000 Open source
20172017-12-31	Operating cash flow	-47371000	Operating Cash Flow: -47371000 Open source
20182018-12-31	Operating cash flow	-68531000	Operating Cash Flow: -68531000 Open source
20192019-12-31	Operating cash flow	-50612000	Operating Cash Flow: -50612000 Open source
20202020-12-31	Operating cash flow	-71260000	Operating Cash Flow: -71260000 Open source
20212021-12-31	Operating cash flow	29131000	Operating Cash Flow: 29131000 Open source
20222022-12-31	Operating cash flow	-133675000	Operating Cash Flow: -133675000 Open source
20232023-12-31	Operating cash flow	-160601000	Operating Cash Flow: -160601000 Open source
20242024-12-31	Operating cash flow	-274903000	Operating Cash Flow: -274903000 Open source
20252025-12-31	Operating cash flow	-322980000	Operating Cash Flow: -322980000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -323.2M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-35418000	Operating Cash Flow: -35157000 Open source Capital Expenditure: 261000 Open source
20172017-12-31	Free cash flow	-47455000	Operating Cash Flow: -47371000 Open source Capital Expenditure: 84000 Open source
20182018-12-31	Free cash flow	-68718000	Operating Cash Flow: -68531000 Open source Capital Expenditure: 187000 Open source
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: -50612000 Open source
20202020-12-31	Free cash flow	-71260000	Operating Cash Flow: -71260000 Open source Capital Expenditure: 0 Open source
20212021-12-31	Free cash flow	29002000	Operating Cash Flow: 29131000 Open source Capital Expenditure: 129000 Open source
20222022-12-31	Free cash flow	-133675000	Operating Cash Flow: -133675000 Open source Capital Expenditure: 0 Open source
20232023-12-31	Free cash flow	-160601000	Operating Cash Flow: -160601000 Open source Capital Expenditure: 0 Open source
20242024-12-31	Free cash flow	-274903000	Operating Cash Flow: -274903000 Open source Capital Expenditure: 0 Open source
20252025-12-31	Free cash flow	-323167000	Operating Cash Flow: -322980000 Open source Capital Expenditure: 187000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

87.8% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	22.8%	Total Liabilities: 24874000 Open source Total Assets: 109013000 Open source
20172017-12-31	Liabilities / assets	24%	Total Liabilities: 32867000 Open source Total Assets: 137186000 Open source
20182018-12-31	Liabilities / assets	36.8%	Total Liabilities: 30891000 Open source Total Assets: 83938000 Open source
20192019-12-31	Liabilities / assets	50.3%	Total Liabilities: 31925000 Open source Total Assets: 63525000 Open source
20202020-12-31	Liabilities / assets	16.1%	Total Liabilities: 48425000 Open source Total Assets: 300613000 Open source
20212021-12-31	Liabilities / assets	9.2%	Total Liabilities: 41289000 Open source Total Assets: 449657000 Open source
20222022-12-31	Liabilities / assets	6%	Total Liabilities: 29787000 Open source Total Assets: 497236000 Open source
20232023-12-31	Liabilities / assets	9.6%	Total Liabilities: 58684000 Open source Total Assets: 612880000 Open source
20242024-12-31	Liabilities / assets	60.2%	Total Liabilities: 436692000 Open source Total Assets: 724816000 Open source
20252025-12-31	Liabilities / assets	87.8%	Total Liabilities: 465076000 Open source Total Assets: 529706000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

4.4× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	10.47×	Current Assets: 108510000 Open source Current Liabilities: 10366000 Open source
20172017-12-31	Current assets / current liabilities	8.45×	Current Assets: 133442000 Open source Current Liabilities: 15798000 Open source
20182018-12-31	Current assets / current liabilities	5.18×	Current Assets: 83346000 Open source Current Liabilities: 16105000 Open source
20192019-12-31	Current assets / current liabilities	3.39×	Current Assets: 62331000 Open source Current Liabilities: 18368000 Open source
20202020-12-31	Current assets / current liabilities	15.84×	Current Assets: 298864000 Open source Current Liabilities: 18872000 Open source
20212021-12-31	Current assets / current liabilities	21.68×	Current Assets: 448396000 Open source Current Liabilities: 20683000 Open source
20222022-12-31	Current assets / current liabilities	16.85×	Current Assets: 489786000 Open source Current Liabilities: 29065000 Open source
20232023-12-31	Current assets / current liabilities	10×	Current Assets: 580876000 Open source Current Liabilities: 58096000 Open source
20242024-12-31	Current assets / current liabilities	5.82×	Current Assets: 603057000 Open source Current Liabilities: 103549000 Open source
20252025-12-31	Current assets / current liabilities	4.4×	Current Assets: 528081000 Open source Current Liabilities: 120116000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 44.47 million Exact value Exact value: -44472000 USD 2016-01-01 – 2016-12-31: -44472000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Syndax Pharmaceuticals Inc · 2016-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Net Income: -44472000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -44472000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459019006772/sndx-20181231.xml#120850 Filing: 000156459019006772 The citation records this snapshot. The page link may show a newer release later.	−USD 35.16 million Exact value Exact value: -35157000 USD 2016-01-01 – 2016-12-31: -35157000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Syndax Pharmaceuticals Inc · 2016-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Operating Cash Flow: -35157000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35157000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459019006772/sndx-20181231.xml#159236 Filing: 000156459019006772 The citation records this snapshot. The page link may show a newer release later.	USD 261,000 Exact value Exact value: 261000 USD 2016-01-01 – 2016-12-31: 261000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Syndax Pharmaceuticals Inc · 2016-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Capital Expenditure: 261000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 261000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459019006772/sndx-20181231.xml#159865 Filing: 000156459019006772 The citation records this snapshot. The page link may show a newer release later.	−USD 35.42 million Calculation and evidence -35157000 − 261000 USD Exact free cash flow: -35418000 USD 2016-01-01 – 2016-12-31: -35157000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 261000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Syndax Pharmaceuticals Inc · 2016-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Free cash flow: -35418000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35157000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459019006772/sndx-20181231.xml#159236 Filing: 000156459019006772 Input fundies:CapitalExpenditure: 261000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459019006772/sndx-20181231.xml#159865 Filing: 000156459019006772 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 60.8 million Exact value Exact value: -60802000 USD 2017-01-01 – 2017-12-31: -60802000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Syndax Pharmaceuticals Inc · 2017-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Net Income: -60802000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -60802000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459020009016/sndx-20191231.xml#159344 Filing: 000156459020009016 The citation records this snapshot. The page link may show a newer release later.	−USD 47.37 million Exact value Exact value: -47371000 USD 2017-01-01 – 2017-12-31: -47371000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Syndax Pharmaceuticals Inc · 2017-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Operating Cash Flow: -47371000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -47371000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459020009016/sndx-20191231.xml#194380 Filing: 000156459020009016 The citation records this snapshot. The page link may show a newer release later.	USD 84,000 Exact value Exact value: 84000 USD 2017-01-01 – 2017-12-31: 84000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Syndax Pharmaceuticals Inc · 2017-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Capital Expenditure: 84000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 84000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459020009016/sndx-20191231.xml#194801 Filing: 000156459020009016 The citation records this snapshot. The page link may show a newer release later.	−USD 47.46 million Calculation and evidence -47371000 − 84000 USD Exact free cash flow: -47455000 USD 2017-01-01 – 2017-12-31: -47371000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 84000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Syndax Pharmaceuticals Inc · 2017-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Free cash flow: -47455000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -47371000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459020009016/sndx-20191231.xml#194380 Filing: 000156459020009016 Input fundies:CapitalExpenditure: 84000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459020009016/sndx-20191231.xml#194801 Filing: 000156459020009016 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 73.96 million Exact value Exact value: -73961000 USD 2018-01-01 – 2018-12-31: -73961000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Syndax Pharmaceuticals Inc · 2018-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Net Income: -73961000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -73961000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459021012607/sndx-10k_20201231.htm#2729524 Filing: 000156459021012607 The citation records this snapshot. The page link may show a newer release later.	−USD 68.53 million Exact value Exact value: -68531000 USD 2018-01-01 – 2018-12-31: -68531000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Syndax Pharmaceuticals Inc · 2018-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Operating Cash Flow: -68531000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -68531000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459021012607/sndx-10k_20201231.htm#2482697 Filing: 000156459021012607 The citation records this snapshot. The page link may show a newer release later.	USD 187,000 Exact value Exact value: 187000 USD 2018-01-01 – 2018-12-31: 187000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Syndax Pharmaceuticals Inc · 2018-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Capital Expenditure: 187000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 187000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459021012607/sndx-10k_20201231.htm#2493209 Filing: 000156459021012607 The citation records this snapshot. The page link may show a newer release later.	−USD 68.72 million Calculation and evidence -68531000 − 187000 USD Exact free cash flow: -68718000 USD 2018-01-01 – 2018-12-31: -68531000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 187000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Syndax Pharmaceuticals Inc · 2018-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Free cash flow: -68718000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -68531000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459021012607/sndx-10k_20201231.htm#2482697 Filing: 000156459021012607 Input fundies:CapitalExpenditure: 187000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459021012607/sndx-10k_20201231.htm#2493209 Filing: 000156459021012607 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 56.05 million Exact value Exact value: -56047000 USD 2019-01-01 – 2019-12-31: -56047000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Syndax Pharmaceuticals Inc · 2019-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Net Income: -56047000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -56047000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459022008112/sndx-10k_20211231.htm#2701556 Filing: 000156459022008112 The citation records this snapshot. The page link may show a newer release later.	−USD 50.61 million Exact value Exact value: -50612000 USD 2019-01-01 – 2019-12-31: -50612000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Syndax Pharmaceuticals Inc · 2019-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Operating Cash Flow: -50612000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -50612000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000156459022008112/sndx-10k_20211231.htm#2417521 Filing: 000156459022008112 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 73.16 million Exact value Exact value: -73158000 USD 2020-01-01 – 2020-12-31: -73158000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Syndax Pharmaceuticals Inc · 2020-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Net Income: -73158000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -73158000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017023005079/sndx-20221231.htm#2881786 Filing: 000095017023005079 The citation records this snapshot. The page link may show a newer release later.	−USD 71.26 million Exact value Exact value: -71260000 USD 2020-01-01 – 2020-12-31: -71260000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Syndax Pharmaceuticals Inc · 2020-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Operating Cash Flow: -71260000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -71260000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017023005079/sndx-20221231.htm#2547059 Filing: 000095017023005079 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2020-01-01 – 2020-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Syndax Pharmaceuticals Inc · 2020-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017023005079/sndx-20221231.htm#2558027 Filing: 000095017023005079 The citation records this snapshot. The page link may show a newer release later.	−USD 71.26 million Calculation and evidence -71260000 − 0 USD Exact free cash flow: -71260000 USD 2020-01-01 – 2020-12-31: -71260000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Syndax Pharmaceuticals Inc · 2020-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Free cash flow: -71260000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -71260000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017023005079/sndx-20221231.htm#2547059 Filing: 000095017023005079 Input fundies:CapitalExpenditure: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017023005079/sndx-20221231.htm#2558027 Filing: 000095017023005079 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 24.93 million Exact value Exact value: 24926000 USD 2021-01-01 – 2021-12-31: 24926000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Syndax Pharmaceuticals Inc · 2021-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Net Income: 24926000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 24926000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017024021253/sndx-20231231.htm#2195994 Filing: 000095017024021253 The citation records this snapshot. The page link may show a newer release later.	USD 29.13 million Exact value Exact value: 29131000 USD 2021-01-01 – 2021-12-31: 29131000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Syndax Pharmaceuticals Inc · 2021-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Operating Cash Flow: 29131000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 29131000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017024021253/sndx-20231231.htm#1966614 Filing: 000095017024021253 The citation records this snapshot. The page link may show a newer release later.	USD 129,000 Exact value Exact value: 129000 USD 2021-01-01 – 2021-12-31: 129000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Syndax Pharmaceuticals Inc · 2021-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Capital Expenditure: 129000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 129000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017024021253/sndx-20231231.htm#1973430 Filing: 000095017024021253 The citation records this snapshot. The page link may show a newer release later.	USD 29 million Calculation and evidence 29131000 − 129000 USD Exact free cash flow: 29002000 USD 2021-01-01 – 2021-12-31: 29131000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 129000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Syndax Pharmaceuticals Inc · 2021-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Free cash flow: 29002000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 29131000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017024021253/sndx-20231231.htm#1966614 Filing: 000095017024021253 Input fundies:CapitalExpenditure: 129000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017024021253/sndx-20231231.htm#1973430 Filing: 000095017024021253 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 149.34 million Exact value Exact value: -149338000 USD 2022-01-01 – 2022-12-31: -149338000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Syndax Pharmaceuticals Inc · 2022-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Net Income: -149338000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -149338000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017025030394/sndx-20241231.htm#2440066 Filing: 000095017025030394 The citation records this snapshot. The page link may show a newer release later.	−USD 133.68 million Exact value Exact value: -133675000 USD 2022-01-01 – 2022-12-31: -133675000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Syndax Pharmaceuticals Inc · 2022-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Operating Cash Flow: -133675000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -133675000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017025030394/sndx-20241231.htm#2138446 Filing: 000095017025030394 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2022-01-01 – 2022-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Syndax Pharmaceuticals Inc · 2022-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017024021253/sndx-20231231.htm#1972093 Filing: 000095017024021253 The citation records this snapshot. The page link may show a newer release later.	−USD 133.68 million Calculation and evidence -133675000 − 0 USD Exact free cash flow: -133675000 USD 2022-01-01 – 2022-12-31: -133675000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Syndax Pharmaceuticals Inc · 2022-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Free cash flow: -133675000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -133675000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017025030394/sndx-20241231.htm#2138446 Filing: 000095017025030394 Input fundies:CapitalExpenditure: 0 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000095017024021253/sndx-20231231.htm#1972093 Filing: 000095017024021253 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 209.36 million Exact value Exact value: -209360000 USD 2023-01-01 – 2023-12-31: -209360000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Syndax Pharmaceuticals Inc · 2023-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Net Income: -209360000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -209360000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2549560 Filing: 000119312526076536 The citation records this snapshot. The page link may show a newer release later.	−USD 160.6 million Exact value Exact value: -160601000 USD 2023-01-01 – 2023-12-31: -160601000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Syndax Pharmaceuticals Inc · 2023-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Operating Cash Flow: -160601000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -160601000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2238250 Filing: 000119312526076536 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2023-01-01 – 2023-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Syndax Pharmaceuticals Inc · 2023-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2247464 Filing: 000119312526076536 The citation records this snapshot. The page link may show a newer release later.	−USD 160.6 million Calculation and evidence -160601000 − 0 USD Exact free cash flow: -160601000 USD 2023-01-01 – 2023-12-31: -160601000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Syndax Pharmaceuticals Inc · 2023-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Free cash flow: -160601000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -160601000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2238250 Filing: 000119312526076536 Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2247464 Filing: 000119312526076536 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 318.76 million Exact value Exact value: -318758000 USD 2024-01-01 – 2024-12-31: -318758000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Syndax Pharmaceuticals Inc · 2024-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Net Income: -318758000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -318758000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2547708 Filing: 000119312526076536 The citation records this snapshot. The page link may show a newer release later.	−USD 274.9 million Exact value Exact value: -274903000 USD 2024-01-01 – 2024-12-31: -274903000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Syndax Pharmaceuticals Inc · 2024-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Operating Cash Flow: -274903000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -274903000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2236356 Filing: 000119312526076536 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Syndax Pharmaceuticals Inc · 2024-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2245811 Filing: 000119312526076536 The citation records this snapshot. The page link may show a newer release later.	−USD 274.9 million Calculation and evidence -274903000 − 0 USD Exact free cash flow: -274903000 USD 2024-01-01 – 2024-12-31: -274903000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Syndax Pharmaceuticals Inc · 2024-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Free cash flow: -274903000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -274903000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2236356 Filing: 000119312526076536 Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2245811 Filing: 000119312526076536 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 285.42 million Exact value Exact value: -285422000 USD 2025-01-01 – 2025-12-31: -285422000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Syndax Pharmaceuticals Inc · 2025-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Net Income: -285422000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -285422000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2545856 Filing: 000119312526076536 The citation records this snapshot. The page link may show a newer release later.	−USD 322.98 million Exact value Exact value: -322980000 USD 2025-01-01 – 2025-12-31: -322980000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Syndax Pharmaceuticals Inc · 2025-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Operating Cash Flow: -322980000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -322980000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2234462 Filing: 000119312526076536 The citation records this snapshot. The page link may show a newer release later.	USD 187,000 Exact value Exact value: 187000 USD 2025-01-01 – 2025-12-31: 187000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Syndax Pharmaceuticals Inc · 2025-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Capital Expenditure: 187000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 187000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2244148 Filing: 000119312526076536 The citation records this snapshot. The page link may show a newer release later.	−USD 323.17 million Calculation and evidence -322980000 − 187000 USD Exact free cash flow: -323167000 USD 2025-01-01 – 2025-12-31: -322980000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 187000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Syndax Pharmaceuticals Inc · 2025-12-31 Syndax Pharmaceuticals Inc (edgar:1395937) Free cash flow: -323167000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:49:37Z Snapshot: 2ebbc1010d5aaff476e6d59490171f63e588226af976306955e99e7b785a2b8a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395937?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -322980000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2234462 Filing: 000119312526076536 Input fundies:CapitalExpenditure: 187000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm#2244148 Filing: 000119312526076536 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

59 filings · 2,728 latest values · 2,728 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001395937, 1395937, SNDX, edgar:1395937

Also known as SYNDAX PHARMACEUTICALS INC, SYNDAX PHARMACEUTICALS, INC., Syndax Pharmaceuticals Inc, Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Inc

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation